stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Operating margin
Viridian Therapeutics, Inc.'s operating margin over the twelve months to 30 September 2026 was −1,781.4%, down 1268.5 percentage points from fiscal 2025 (−512.9%). Over the past ten years it has ranged from −99,018.2% (fiscal 2024) to −394.5% (fiscal 2018); the current reading is higher than 73% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | −512.9% | 98,505.30 |
| FY2024 | −99,018.2% | (17,983.18) |
| FY2023 | −81,035.0% | (73,455.80) |
| FY2022 | −7,579.2% | (4,888.44) |
| FY2021 | −2,690.8% | 7,821.59 |
| FY2020 | −10,512.4% | (9,571.36) |
| FY2019 | −941.0% | (546.51) |
| FY2018 | −394.5% | 268.29 |
| FY2017 | −662.8% | (174.25) |
| FY2016 | −488.6% | (47.77) |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Sep 2026 | −401.8% | 44,058.74 |
| Jun 2026 | −44,460.6% | 37,928.80 |
| Mar 2026 | −82,389.4% | 10,602.31 |
| Dec 2025 | −92,991.7% | (92,934.97) |
| 43 more quarters | Free account |
Against its own ten years
Operating margin against peers
| Company | Operating margin |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 0.00% |
| DYN Dyne Therapeutics, Inc. compare | 0.00% |
| CELC Celcuity, Inc. compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −102.0% |
| IDYA IDEAYA Biosciences, Inc. compare | −1,267.4% |
| VRDN Viridian Therapeutics, Inc. | −1,781.4% |
| DNLI Denali Therapeutics Inc. compare | −2,349.0% |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on VRDN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement